{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:00:06Z","timestamp":1768438806286,"version":"3.49.0"},"reference-count":60,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oxidative stress is strongly linked to neurodegeneration through the activation\nof c-Abl kinase, which arrests \u03b1-synuclein proteolysis by interacting with parkin interacting substrate\n(PARIS) and aminoacyl tRNA synthetase complex-interacting multifunctional protein 2\n(AIMP2). This activation, triggered by ataxia-telangiectasia mutated (ATM) kinase, leads to dopaminergic\nneuron loss and \u03b1-synuclein aggregation, a critical pathophysiological aspect of Parkinson\u2019s\ndisease (PD). To halt PD progression, pharmacological inhibition of c-Abl kinase is essential. Despite\nthree generations of tyrosine kinase inhibitors (TKIs) being explored for PD treatment, they present\nsignificant concerns including poor blood-brain barrier penetration, off-target effects, and severe side\neffects. Notably, there are currently no FDA-approved c-Abl kinase inhibitors in clinical usage for PD\ntreatment, highlighting the urgent need for potent, safe, and cost-effective alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aims to identify potential c-Abl kinase inhibitors from plant-derived compounds\nwith reported anti-Parkinson's potential and their derivatives using molecular docking, molecular\ndynamics simulations (MDS), and in silico pharmacokinetics and toxicity profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Seventy-eight compounds sourced from literature were docked against c-Abl kinase using\nMaestro 12.5. The top three hit compounds, along with nilotinib (control drug), were subjected\nto drug-likeness, ADMET profiling using the AI Drug Lab server and 100 ns MDS using Desmond.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Amburoside A, diarylheptanoid MS13, and dimethylaminomethyl-substituted-curcumin\nshowed binding affinities close to nilotinib, with values of -12.615, -12.556, and -11.895 kcal\/mol\nrespectively, compared to nilotinib's -16.826 kcal\/mol. The three plant-derived compounds exhibited\nexcellent structural stability and favorable ADMET profiles, including optimal blood-brain barrier\npermeation<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The three hit compounds identified in this study show potential as c-Abl kinase inhibitors.\nGiven the absence of FDA-approved c-Abl kinase inhibitors for PD, these findings are significant\nas they could contribute new therapeutic options for the treatment and management of PD.\nHowever, further in vitro and in vivo experiments are necessary to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115734064310145240822060730","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:04:01Z","timestamp":1736917441000},"page":"969-986","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Integrative Computational Approach for the Identification of C-Abl Kinase Inhibitors from Anti-Parkinson Plant-Derived Bioactive"],"prefix":"10.2174","volume":"21","author":[{"given":"Haruna Isiyaku","family":"Umar","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Federal University of Technology, P. M. B. 704, Akure, Ondo State, Nigeria"},{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab","family":"Ashimiyu-Abdusalam","sequence":"additional","affiliation":[{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"},{"name":"Department of Biochemistry and Nutrition, Nigerian Institute of Medical Research, Yaba, Lagos State, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Bhupal Nobles\u2019 College of Pharmacy, Udaipur, Rajasthan, India-313001"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najwa Ahmad","family":"Kuthi","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Faculty of Science, Universiti Teknologi Malaysia (UTM), Johor Bahru, Johor, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omoboyede","family":"Victor","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Federal University of Technology, P. M. B. 704, Akure, Ondo State, Nigeria"},{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zainab Naeem","family":"Abdulsalam","sequence":"additional","affiliation":[{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Oluwabunmi","family":"Aribo","sequence":"additional","affiliation":[{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridwan Opeyemi","family":"Bello","sequence":"additional","affiliation":[{"name":"Computer- Aided Therapeutic Discovery and Design Platform, Federal University of Technology, P. M. B. 704, Akure, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef A.","family":"Bin Jardan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 11451, Riyadh, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiba-Allah","family":"Nafidi","sequence":"additional","affiliation":[{"name":"Department of Food Science, Faculty of Agricultural and Food Sciences, Laval University, 2325 Quebec City, QC G1V 0A6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Bourhia","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Faculty of Medicine and Pharmacy, Ibn Zohr University, Laayoune 70000, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.parkreldis.2022.07.014","volume":"102","author":"Albrecht F.","year":"2022","unstructured":"Albrecht F.; Poulakis K.; Freidle M.; Johansson H.; Ekman U.; Volpe G.; Westman E.; Pereira J.B.; Franz\u00e9n E.; Unraveling parkinson\u2019s disease heterogeneity using subtypes based on multimodal data. Parkinsonism Relat Disord  2022,102,19-29","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"Brahmachari S.","year":"2016","unstructured":"Brahmachari S.; Ge P.; Lee S.H.; Kim D.; Karuppagounder S.S.; Kumar M.; Mao X.; Shin J.H.; Lee Y.; Pletnikova O.; Troncoso J.C.; Dawson V.L.; Dawson T.M.; Ko H.S.; Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein\u2013induced neurodegeneration. J Clin Invest  2016,126(8),2970-2988","journal-title":"J Clin Invest"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.52586\/5007","volume":"26","author":"Saleem U.","year":"2021","unstructured":"Saleem U.; Bibi S.; Shah M.A.; Ahmad B.; Saleem A.; Chauhdary Z.; Anti-Parkinson\u2019s evaluation of Brassica juncea leaf extract and underlying mechanism of its phytochemicals. IMR Press  2021,26(11),1031-1051","journal-title":"IMR Press"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1021\/acsmedchemlett.9b00612","volume":"11","author":"Kaiser T.M.","year":"2020","unstructured":"Kaiser T.M.; Dentmon Z.W.; Dalloul C.E.; Sharma S.K.; Liotta D.C.; Accelerated discovery of novel ponatinib analogs with improved properties for the treatment of parkinson\u2019s disease. ACS Med Chem Lett  2020,11(4),491-496","journal-title":"ACS Med Chem Lett"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.bbabio.2015.04.010","volume":"1847","author":"Lionaki E.","year":"2015","unstructured":"Lionaki E.; Markaki M.; Palikaras K.; Tavernarakis N.; Mitochondria, autophagy and age-associated neurodegenerative diseases: New insights into a complex interplay. Biochim Biophys Acta Bioenerg  2015,1847(11),1412-1423","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnagi.2016.00254","volume":"8","author":"Lindholm D.","year":"2016","unstructured":"Lindholm D.; Pham D.D.; Cascone A.; Eriksson O.; Wennerberg K.; Saarma M.; c-Abl inhibitors enable insights into the pathophysiology and neuroprotection in parkinson\u2019s disease. Front Aging Neurosci  2016,8,254","journal-title":"Front Aging Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-020-00364-w","volume":"15","author":"Karim M.R.","year":"2020","unstructured":"Karim M.R.; Liao E.E.; Kim J.; Meints J.; Martinez H.M.; Pletnikova O.; Troncoso J.C.; Lee M.K.; \u03b1-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment. Mol Neurodegener  2020,15(1),27","journal-title":"Mol Neurodegener"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.parkreldis.2023.105281","author":"Walsh R.R.","year":"2023","unstructured":"Walsh R.R.; Damle N.K.; Mandhane S.; Piccoli S.P.; Talluri R.S.; Love D.; Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson\u2019s disease. Parkinsonism Relat Disord  2023,105281","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.pneurobio.2021.102070","volume":"202","author":"Ghosh S.","year":"2021","unstructured":"Ghosh S.; Won S.J.; Wang J.; Fong R.; Butler N.J.M.; Moss A.; Wong C.; Pan J.; Sanchez J.; Huynh A.; Wu L.; Manfredsson F.P.; Swanson R.A.; \u03b1-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism. Prog Neurobiol  2021,202,102070","journal-title":"Prog Neurobiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/aian.AIAN_177_18","volume":"22","author":"Goyal V.","year":"2019","unstructured":"Goyal V.; Dash D.; Anticancer drugs for parkinson\u2019s disease: Is it a ray of hope or only hype? Ann Indian Acad Neurol  2019,22(1),13-16","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/md18070347","volume":"18","author":"Hannan M.A.","year":"2020","unstructured":"Hannan M.A.; Dash R.; Haque M.N.; Mohibbullah M.; Sohag A.A.M.; Rahman M.A.; Uddin M.J.; Alam M.; Moon I.S.; Neuroprotective potentials of marine algae and their bioactive metabolites: Pharmacological insights and therapeutic advances. Mar Drugs  2020,18(7),347","journal-title":"Mar Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-171191","volume":"7","author":"Brahmachari S.","year":"2017","unstructured":"Brahmachari S.; Karuppagounder S.S.; Ge P.; Lee S.; Dawson V.L.; Dawson T.M.; Ko H.S.; c-Abl and parkinson\u2019s disease: Mechanisms and therapeutic potential. J Parkinsons Dis  2017,7(4),589-601","journal-title":"J Parkinsons Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","volume":"133","author":"Barodia S.K.","year":"2017","unstructured":"Barodia S.K.; Creed R.B.; Goldberg M.S.; Parkin and PINK1 functions in oxidative stress and neurodegeneration. Brain Res Bull  2017,133,51-59","journal-title":"Brain Res Bull"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2018.04.004","volume":"697","author":"Chu C.T.","year":"2019","unstructured":"Chu C.T.; Multiple pathways for mitophagy: A neurodegenerative conundrum for parkinson\u2019s disease. Neurosci Lett  2019,697,66-71","journal-title":"Neurosci Lett"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ibneur.2022.10.006","volume":"13","author":"Mar\u00edn T.","year":"2022","unstructured":"Mar\u00edn T.; Valls C.; Jerez C.; Elgueta D.; Vidal L.; Alvarez A.R.; The c-Abl\/p73 pathway induces neurodegeneration in a Parkinson\u2019s disease model. IBRO Neurosci Rep  2022,13,378-387","journal-title":"IBRO Neurosci Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.7150\/ijms.73740","volume":"19","author":"Feng L.","year":"2022","unstructured":"Feng L.; Fu S.; Yao Y.; Li Y.; Xu L.; Zhao Y.; Luo L.; Roles for c-Abl in postoperative neurodegeneration. Int J Med Sci  2022,19(12),1753-1761","journal-title":"Int J Med Sci"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9233749","author":"Zhang Y.","year":"2022","unstructured":"Zhang Y.; Wu J.; Jin W.; Shen M.; Yin S.; Lai X.; Nonreceptor tyrosine kinase c-abl-mediated phb2 phosphorylation aggravates mitophagy disorder in parkinson\u2019s disease model. Wiley Online Library  2022","journal-title":"Wiley Online Library"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"Weisberg E.","year":"2005","unstructured":"Weisberg E.; Manley P.W.; Breitenstein W.; Br\u00fcggen J.; Cowan-Jacob S.W.; Ray A.; Huntly B.; Fabbro D.; Fendrich G.; Hall-Meyers E.; Kung A.L.; Mestan J.; Daley G.Q.; Callahan L.; Catley L.; Cavazza C.; Mohammed A.; Neuberg D.; Wright R.D.; Gilliland D.G.; Griffin J.D.; Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell  2005,7(2),129-141","journal-title":"Cancer Cell"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10072-016-2808-2","volume":"38","author":"Zhou Z.H.","year":"2017","unstructured":"Zhou Z.H.; Wu Y.F.; Wang X.; Han Y.Z.; The c-Abl inhibitor in parkinson disease. Neurol Sci  2017,38(4),547-552","journal-title":"Neurol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1093\/brain\/awab356","volume":"144","author":"Kim H.","year":"2021","unstructured":"Kim H.; Shin J.Y.; Jo A.; Kim J.H.; Park S.; Choi J.Y.; Kang H.C.; Dawson V.L.; Dawson T.M.; Shin J.H.; Lee Y.; Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Brain  2021,144(12),3674-3691","journal-title":"Brain"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cells11243972","volume":"11","author":"Lee S.","year":"2022","unstructured":"Lee S.; Ryu H.G.; Kweon S.H.; Kim H.; Park H.; Lee K.H.; Jang S.M.; Na C.H.; Kim S.; Ko H.S.; c-Abl regulates the pathological deposition of TDP-43 via tyrosine 43 phosphorylation. Cells  2022,11(24),3972","journal-title":"Cells"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","volume":"37","author":"Werner M.H.","year":"2022","unstructured":"Werner M.H.; Olanow C.W.; Parkinson\u2019s disease modification through abl kinase inhibition: An opportunity. Mov Disord  2022,37(1),6-15","journal-title":"Mov Disord"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e00470","DOI":"10.1002\/prp2.470","volume":"7","author":"Pagan F.L.","year":"2019","unstructured":"Pagan F.L.; Hebron M.L.; Wilmarth B.; Torres-Yaghi Y.; Lawler A.; Mundel E.E.; Yusuf N.; Starr N.J.; Arellano J.; Howard H.H.; Peyton M.; Matar S.; Liu X.; Fowler A.J.; Schwartz S.L.; Ahn J.; Moussa C.; Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson\u2019s disease. Pharmacol Res Perspect  2019,7(2),e00470","journal-title":"Pharmacol Res Perspect"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1093\/hmg\/ddy143","volume":"27","author":"Lee S.","year":"2018","unstructured":"Lee S.; Kim S.; Park Y.J.; Yun S.P.; Kwon S.H.; Kim D.; Kim D.Y.; Shin J.S.; Cho D.J.; Lee G.Y.; Ju H.S.; Yun H.J.; Park J.H.; Kim W.R.; Jung E.A.; Lee S.; Ko H.S.; The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson\u2019s disease mouse model. Hum Mol Genet  2018,27(13),2344-2356","journal-title":"Hum Mol Genet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.clml.2021.11.012","volume":"22","author":"Sacha T.","year":"2022","unstructured":"Sacha T.; Szczepanek E.; Dumnicka P.; G\u00f3ra-Tybor J.; Niesiob\u0119dzka-Kr\u0119\u017cel J.; Prejzner W.; Wasilewska E.; K\u0142oczko J.; Ciep\u0142uch H.; Makowska W.; Patkowska E.; Wasilewska J.; Bober G.; Kopera M.; Wichary R.; Kroll-Balcerzak R.; Gromek T.; Wach M.; Rudkowska-Kazanowska A.; \u015awiniarska M.; Paczkowska E.; Biernat M.; Joks M.; Oller M.; Kasza R.; Kostyra A.; Gil J.; Grzybowska-Izydorczyk O.; The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in poland within the donation program. Clin Lymphoma Myeloma Leuk  2022,22(6),405-415","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3389\/fphar.2018.01311","volume":"9","author":"Zhou Y.","year":"2018","unstructured":"Zhou Y.; Yamamura Y.; Ogawa M.; Tsuji R.; Tsuchiya K.; Kasahara J.; Goto S.; c-Abl inhibition exerts symptomatic antiparkinsonian effects through a striatal postsynaptic mechanism. Front Pharmacol  2018,9,1311","journal-title":"Front Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/13880209.2019.1618344","volume":"57","author":"Rabiei Z.","year":"2019","unstructured":"Rabiei Z.; Solati K.; Amini-Khoei H.; Phytotherapy in treatment of Parkinson\u2019s disease: A review. Pharm Biol  2019,57(1),355-362","journal-title":"Pharm Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e02437","DOI":"10.1016\/j.heliyon.2019.e02437","volume":"5","author":"Sharma P.","year":"2019","unstructured":"Sharma P.; Dwivedee B.P.; Bisht D.; Dash A.K.; Kumar D.; The chemical constituents and diverse pharmacological importance of Tinospora cordifolia. Heliyon  2019,5(9),e02437","journal-title":"Heliyon"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.34172\/apb.2021.026","volume":"11","author":"Khazdair M.R.","year":"2021","unstructured":"Khazdair M.R.; Kianmehr M.; Anaeigoudari A.; Effects of medicinal plants and flavonoids on parkinson\u2019s disease: A review on basic and clinical evidences. Adv Pharm Bull  2021,11(2),224-232","journal-title":"Adv Pharm Bull"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"6687572","DOI":"10.1155\/2021\/6687572","author":"Kulkarni A.M.","year":"2021","unstructured":"Kulkarni A.M.; Rampogu S.; Lee K.W.; Computer-aided drug discovery identifies alkaloid inhibitors of parkinson\u2019s disease associated protein, prolyl oligopeptidase. Evid Based Complement Alternat Med  2021,6687572","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1570159X15666171128145423","volume":"16","author":"Ishiki H.M.","year":"2018","unstructured":"Ishiki H.M.; Filho J.M.B.; da Silva M.S.; Scotti M.T.; Scotti L.; Scotti L.; Computer-aided drug design applied to parkinson targets. Curr Neuropharmacol  2018,16(6),865-880","journal-title":"Curr Neuropharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules26082193","volume":"26","author":"Cruz-Vicente P.","year":"2021","unstructured":"Cruz-Vicente P.; Passarinha L.A.; Silvestre S.; Gallardo E.; Recent developments in new therapeutic agents against alzheimer and parkinson diseases: In-Silico approaches. Molecules  2021,26(8),2193","journal-title":"Molecules"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13065-023-00939-w","volume":"17","author":"Ece A.","year":"2023","unstructured":"Ece A.; Computer-aided drug design. BMC Chem  2023,17(1),26","journal-title":"BMC Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/bioengineering8020030","volume":"8","author":"Aldewachi H.","year":"2021","unstructured":"Aldewachi H.; Al-Zidan R.N.; Conner M.T.; Salman M.M.; High-throughput screening platforms in the discovery of novel drugs for neurodegenerative diseases. Bioengineering  2021,8(2),30","journal-title":"Bioengineering"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2174\/1570159X16666180315142137","volume":"16","author":"Sehgal S.A.","year":"2018","unstructured":"Sehgal S.A.; Hammad M.A.; Tahir R.A.; Akram H.N.; Ahmad F.; Current therapeutic molecules and targets in neurodegenerative diseases based on in silico drug design. Curr Neuropharmacol  2018,16(6),649-663","journal-title":"Curr Neuropharmacol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.3390\/ijms22094688","volume":"22","author":"Salman M.M.","year":"2021","unstructured":"Salman M.M.; Al-Obaidi Z.; Kitchen P.; Loreto A.; Bill R.M.; Wade-Martins R.; Advances in applying computer-aided drug design for neurodegenerative diseases. Int J Mol Sci  2021,22(9),4688","journal-title":"Int J Mol Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1208\/s12249-022-02268-y","volume":"23","author":"Idoudi S.","year":"2022","unstructured":"Idoudi S.; Bedhiafi T.; Hijji Y.M.; Billa N.; Curcumin and derivatives in nanoformulations with therapeutic potential on colorectal cancer. AAPS PharmSciTech  2022,23(5),115","journal-title":"AAPS PharmSciTech"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.3390\/molecules24234386","volume":"24","author":"Mbese Z.","year":"2019","unstructured":"Mbese Z.; Khwaza V.; Aderibigbe B.A.; Curcumin and its derivatives as potential therapeutic agents in prostate, colon and breast cancers. Molecules  2019,24(23),4386","journal-title":"Molecules"},{"key":"ref=39","first-page":"472","volume":"11","author":"Oglah M.K.","year":"2020","unstructured":"Oglah M.K.; Mustafa Y.F.; Bashir M.K.; Jasim M.H.; Curcumin and its derivatives: A review of their biological activities. Systematic Review Pharmacy  2020,11,472-481","journal-title":"Systematic Review Pharmacy"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/biom10010059","volume":"10","author":"Khan H.","year":"2020","unstructured":"Khan H.; Ullah H.; Aschner M.; Cheang W.S.; Neuroprotective effects of quercetin in alzheimer\u2019s disease. Biomolecules  2020,10(1),59","journal-title":"Biomolecules"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3390\/antiox12030744","volume":"12","author":"Ahmed S.H.H.","year":"2023","unstructured":"Ahmed S.H.H.; Gonda T.; Agbadua O.G.; Girst G.; Berkecz R.; K\u00fasz N.; Tsai M.C.; Wu C.C.; Balogh G.T.; Hunyadi A.; Preparation and evaluation of 6-gingerol derivatives as novel antioxidants and antiplatelet agents. Antioxidants  2023,12(3),744","journal-title":"Antioxidants"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/antiox12020475","volume":"12","author":"Mak K.K.","year":"2023","unstructured":"Mak K.K.; Shiming Z.; Sakirolla R.; Balijepalli M.K.; Dinkova-Kostova A.T.; Epemolu O.; Mohd Z.; Pichika M.R.; Synthesis of new shogaol analogues as NRF2 activators and evaluation of their anti-inflammatory activity, modes of action and metabolic stability. Antioxidants  2023,12(2),475","journal-title":"Antioxidants"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","volume":"12","author":"Harder E.","year":"2016","unstructured":"Harder E.; Damm W.; Maple J.; Wu C.; Reboul M.; Xiang J.Y.; Wang L.; Lupyan D.; Dahlgren M.K.; Knight J.L.; Kaus J.W.; Cerutti D.S.; Krilov G.; Jorgensen W.L.; Abel R.; Friesner R.A.; OPLS3: A force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput  2016,12(1),281-296","journal-title":"J Chem Theory Comput"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00894-022-05373-8","volume":"28","author":"Tian H.","year":"2022","unstructured":"Tian H.; Ketkar R.; Tao P.; ADMETboost: A web server for accurate ADMET prediction. J Mol Model  2022,28(12),408","journal-title":"J Mol Model"},{"key":"ref=45","first-page":"37","volume":"8","author":"Hospital A.","year":"2015","unstructured":"Hospital A.; Go\u00f1i J.R.; Orozco M.; Gelp\u00ed J.L.; Molecular dynamics simulations: Advances and applications. Adv Appl Bioinform Chem  2015,8,37-47","journal-title":"Adv Appl Bioinform Chem"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1017\/jfm.2011.18","volume":"675","author":"Kumar A.","year":"2011","unstructured":"Kumar A.; Higdon J.J.L.; Particle mesh ewald stokesian dynamics simulations for suspensions of non-spherical particles. J Fluid Mech  2011,675,297-335","journal-title":"J Fluid Mech"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"110238","DOI":"10.1016\/j.jcp.2021.110238","volume":"435","author":"Barclay P.L.","year":"2021","unstructured":"Barclay P.L.; Zhang D.Z.; Periodic boundary conditions for arbitrary deformations in molecular dynamics simulations. J Comput Phys  2021,435,110238","journal-title":"J Comput Phys"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","volume":"31","author":"Hoover W.G.","year":"1985","unstructured":"Hoover W.G.; Canonical dynamics: Equilibrium phase-space distributions. Phys Rev A Gen Phys  1985,31(3),1695-1697","journal-title":"Phys Rev A Gen Phys"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/molecules27134098","volume":"27","author":"Aziz M.","year":"2022","unstructured":"Aziz M.; Ejaz S.A.; Zargar S.; Akhtar N.; Aborode A.T.; A Wani T.; Batiha G.E.; Siddique F.; Alqarni M.; Akintola A.A.; Deep learning and structure-based virtual screening for drug discovery against NEK7: A novel target for the treatment of cancer. Molecules  2022,27(13),27","journal-title":"Molecules"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s11030-023-10689-5","volume":"28","author":"Danazumi A.U.","year":"2024","unstructured":"Danazumi A.U.; Umar H.I.; You must be flexible enough to be trained, Mr. Dynamics simulator. Mol Divers  2024,28(4),2731-2733","journal-title":"Mol Divers"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e25678","DOI":"10.1002\/qua.25678","volume":"119","author":"Cavasotto C.N.","year":"2019","unstructured":"Cavasotto C.N.; Aucar M.G.; Adler N.S.; Computational chemistry in drug lead discovery and design. Int J Quantum Chem  2019,119(2),e25678","journal-title":"Int J Quantum Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/ijms17020144","volume":"17","author":"Du X.","year":"2016","unstructured":"Du X.; Li Y.; Xia Y.L.; Ai S.M.; Liang J.; Sang P.; Ji X.L.; Liu S.Q.; Insights into protein\u2013ligand interactions: Mechanisms, models, and methods. Int J Mol Sci  2016,17(2),144","journal-title":"Int J Mol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","volume":"99","author":"Hollingsworth S.A.","year":"2018","unstructured":"Hollingsworth S.A.; Dror R.O.; Molecular dynamics simulation for all. Neuron  2018,99(6),1129-1143","journal-title":"Neuron"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","volume":"6","author":"Tran J.","year":"2020","unstructured":"Tran J.; Anastacio H.; Bardy C.; Genetic predispositions of Parkinson\u2019s disease revealed in patient-derived brain cells. NPJ Parkinsons Dis  2020,6(1),8","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.curtheres.2022.100676","volume":"96","author":"Sadatmadani S.F.","year":"2022","unstructured":"Sadatmadani S.F.; Malakoutikhah Z.; Mohaghegh F.; Peikar M.; Saboktakin M.; Nilotinib-induced elephantine psoriasis in a patient with chronic myeloid leukemia: A rare case report and literature review. Curr Ther Res Clin Exp  2022,96,100676","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11030-023-10796-3","author":"Rymbai E.","year":"2024","unstructured":"Rymbai E.; Roy D.; Jupudi S.; Srinivasadesikan V.; The identification of c-Abl inhibitors as potential agents for Parkinson\u2019s disease: A preliminary in silico approach. Mol Divers  2024,1-15","journal-title":"Mol Divers"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neulet.2005.06.034","volume":"388","author":"Leal L.K.A.M.","year":"2005","unstructured":"Leal L.K.A.M.; J\u00fanior H.V.N.; Cunha G.M.A.; Moraes M.O.; Pessoa C.; Oliveira R.A.; Silveira E.R.; Canuto K.M.; Viana G.S.B.; Amburoside A, a glucoside from Amburana cearensis, protects mesencephalic cells against 6-hydroxydopamine-induced neurotoxicity. Neurosci Lett  2005,388(2),86-90","journal-title":"Neurosci Lett"},{"key":"ref=58","first-page":"321","volume":"6","author":"Lv H.","year":"2012","unstructured":"Lv H.; She G.; Naturally occurring diarylheptanoids-a supplementary version. Rec Nat Prod  2012,6(4),321-333","journal-title":"Rec Nat Prod"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"29376","DOI":"10.1039\/D1RA03592D","volume":"11","author":"Li T.","year":"2021","unstructured":"Li T.; Pan D.; Pang Q.; Zhou M.; Yao X.; Yao X.; Li H.; Yu Y.; Diarylheptanoid analogues from the rhizomes of Zingiber officinale and their anti-tumour activity. RSC Adv  2021,11(47),29376-29384","journal-title":"RSC Adv"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/d41573-023-00024-w","volume":"22","author":"Crunkhorn S.","year":"2023","unstructured":"Crunkhorn S.; Suppressing c-Abl in parkinson disease. Res Gate  2023,22(3),183","journal-title":"Res Gate"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064310145240822060730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238420\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115734064310145240822060730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:45:36Z","timestamp":1761547536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238420\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115734064310145240822060730","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}